Skip to main content

Table 2 Seroprevalence of SARS-CoV-2 according to contact history and clinical characteristics

From: Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile

 

Participants (n = 2493)

Seropositive participants (n = 242)

Seroprevalencea % (95% CI)

OR (95% CI)

COVID-19 diagnosis (n = 2493):

 -No

2373

144

6.4 (4.7–8.8)

Ref

 -Yes

120

98

68.8 (43.5–86.3)

32.0 (10.7–96.3)

COVID-19 hospitalization (n = 120):

 -No

109

88

69.5 (50.8–83.4)

Ref

 -Yes

11

10

59.3 (43.7–73.3)

0.6 (0.2–1.8)

Contact with confirmed cases (n = 2492):

 -No

2196

135

7.4 (5.3–10.2)

Ref

 -Yes (≥ 1 person)

296

107

31.2 (20.2–44.8)

5.7 (3.0–10.9)

Exposure site (n = 296):

 -At home

197

82

42.1 (21.1–58.7)

3.9 (1.1–13.2)

 -Work/small gatherings/others

99

25

15.8 (6.3–34.5)

Ref

Quarantine (n = 296):

  -No

123

32

21.9 (10.9–39.1)

Ref

  -Yes

173

75

41.0 (24.9–59.3)

2.5 (0.9–7.3)

Any symptom:b

  -No

1841

89

5.2 (3.5–7.7)

Ref

  -Yes

652

153

23.6 (17.1–31.6)

5.6 (3.03–9.4)

Number of symptoms:

 -None

1841

89

5.2 (3.5–7.7)

Ref

 -1–2 symptoms

275

32

19.1 (9.8–33.9)

4.3 (1.8–10.0)

 -2–3 symptoms

195

46

19.6 (11.5–31.2)

4.4 (2.1–9.2)

 -≥ 5 symptoms

182

75

38.1 (24.6–53.8)

11.2 (5.6–22.3)

Seek medical care (n = 651):

 -No

399

64

17.7 (11.5–26.1)

Ref

 -Yes

252

89

32.2 (21.5–45.1)

2.21 (1.1–4.4)

  1. Chile 2020
  2. OR, odds ratio; ref, reference category; 95% CI, 95% confidence interval. aWeighted for sampling weights. bCOVID-19 compatible symptoms including fever, cough, odynophagia, dyspnea, headache, myalgia, chest pain, abdominal pain, diarrhea, fatigue, anosmia and dysgeusia